US Bancorp DE lowered its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 12.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 83,470 shares of the company’s stock after selling 12,249 shares during the period. US Bancorp DE’s holdings in Sanofi were worth $4,499,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in the stock. SRS Capital Advisors Inc. raised its position in shares of Sanofi by 289.1% in the first quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock worth $25,000 after buying an additional 344 shares in the last quarter. Fairfield Bush & CO. purchased a new stake in Sanofi during the first quarter valued at about $26,000. Eagle Bay Advisors LLC purchased a new stake in Sanofi during the second quarter valued at about $28,000. Disciplined Investments LLC raised its position in Sanofi by 2,270.8% during the first quarter. Disciplined Investments LLC now owns 569 shares of the company’s stock valued at $31,000 after purchasing an additional 545 shares in the last quarter. Finally, Norwood Financial Corp purchased a new stake in Sanofi during the second quarter valued at about $31,000. Hedge funds and other institutional investors own 10.06% of the company’s stock.
Sanofi Stock Down 1.1 %
Shares of NASDAQ:SNY opened at $46.50 on Tuesday. The stock’s 50-day moving average price is $51.05 and its 200-day moving average price is $52.21. Sanofi has a 12-month low of $42.63 and a 12-month high of $57.82. The stock has a market capitalization of $117.62 billion, a P/E ratio of 14.58, a price-to-earnings-growth ratio of 2.04 and a beta of 0.60. The company has a current ratio of 1.21, a quick ratio of 0.81 and a debt-to-equity ratio of 0.20.
Analyst Ratings Changes
A number of research firms have weighed in on SNY. StockNews.com began coverage on Sanofi in a research report on Thursday, October 5th. They set a “buy” rating on the stock. Stifel Nicolaus downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Finally, Berenberg Bank upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $60.00.
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
- Five stocks we like better than Sanofi
- How to Read Stock Charts for Beginners
- Safeguard your portfolio with these three bargain stocks
- Your Comprehensive Guide to Investing in Bank Stocks
- Membership clubs gain leverage for the consumer rebound
- What is the FTSE 100 index?
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.